| Primary |
| Hypertension |
40.0% |
| Chronic Obstructive Pulmonary Disease |
20.0% |
| Pneumonia |
13.3% |
| Type 1 Diabetes Mellitus |
13.3% |
| Coronary Artery Disease |
6.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
6.7% |
|
|
| Secondary |
| Product Used For Unknown Indication |
28.8% |
| Drug Use For Unknown Indication |
12.5% |
| Hypertension |
9.1% |
| Foetal Exposure During Pregnancy |
6.0% |
| Maternal Exposure Timing Unspecified |
6.0% |
| Pyrexia |
4.9% |
| Diabetes Mellitus |
3.7% |
| Metastatic Renal Cell Carcinoma |
3.5% |
| Cough |
3.1% |
| Bronchitis |
2.9% |
| Coronary Artery Disease |
2.9% |
| Infection |
2.9% |
| Lung Disorder |
2.5% |
| Pneumonia |
2.5% |
| Nausea |
1.5% |
| Respiratory Distress |
1.5% |
| Sepsis |
1.5% |
| Urinary Tract Infection |
1.5% |
| Arthritis |
1.3% |
| Epilepsy |
1.3% |
|
| Laryngeal Dyspnoea |
8.9% |
| Premature Baby |
8.9% |
| Clostridium Difficile Colitis |
7.6% |
| Toxic Epidermal Necrolysis |
7.6% |
| Foetal Growth Restriction |
6.3% |
| Hepatitis Fulminant |
6.3% |
| Liver Disorder |
5.1% |
| Maternal Exposure Timing Unspecified |
5.1% |
| Rhabdomyolysis |
5.1% |
| Septic Shock |
5.1% |
| Skin Exfoliation |
5.1% |
| Eosinophilic Pneumonia |
3.8% |
| Neutropenia |
3.8% |
| Stevens-johnson Syndrome |
3.8% |
| Thrombocytopenia |
3.8% |
| Toxic Skin Eruption |
3.8% |
| Hepatic Enzyme Abnormal |
2.5% |
| Hepatitis Toxic |
2.5% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.5% |
| Pancreatitis |
2.5% |
|
| Concomitant |
| Drug Use For Unknown Indication |
15.6% |
| Product Used For Unknown Indication |
15.6% |
| B-cell Lymphoma |
7.3% |
| Prophylaxis |
7.2% |
| Psoriasis |
6.1% |
| Rash |
4.2% |
| Cardiac Failure |
4.0% |
| Hypertension |
4.0% |
| Pain |
4.0% |
| Antibiotic Therapy |
3.8% |
| Pneumonia |
3.3% |
| Asthma |
3.1% |
| Diabetes Mellitus |
3.1% |
| Bronchiectasis |
3.0% |
| Sinusitis |
3.0% |
| Atrial Fibrillation |
2.8% |
| Breast Cancer |
2.6% |
| Lung Disorder |
2.4% |
| Multiple Myeloma |
2.4% |
| Lung Infection |
2.3% |
|
| Renal Failure Acute |
20.7% |
| Pyrexia |
8.7% |
| Renal Failure |
7.6% |
| Myalgia |
5.4% |
| Skin Infection |
5.4% |
| Thrombocytopenia |
5.4% |
| White Blood Cell Count Increased |
5.4% |
| Hepatic Function Abnormal |
4.3% |
| Pulmonary Fibrosis |
4.3% |
| Agranulocytosis |
3.3% |
| Lung Disorder |
3.3% |
| Maternal Condition Affecting Foetus |
3.3% |
| Neutropenia |
3.3% |
| Pneumonia Primary Atypical |
3.3% |
| Sepsis |
3.3% |
| Urinary Retention |
3.3% |
| Wound Treatment |
3.3% |
| Cardiac Failure Congestive |
2.2% |
| Completed Suicide |
2.2% |
| Drug Interaction |
2.2% |
|
| Interacting |
| Hypertension |
31.5% |
| Chronic Obstructive Pulmonary Disease |
15.3% |
| Pneumonia |
9.0% |
| Type 1 Diabetes Mellitus |
7.2% |
| Coronary Artery Disease |
5.4% |
| Prophylaxis Against Gastrointestinal Ulcer |
4.5% |
| Urinary Tract Infection |
4.5% |
| Hyperlipidaemia |
3.6% |
| Diabetes Mellitus |
2.7% |
| Flatulence |
2.7% |
| Arrhythmia |
1.8% |
| Helicobacter Infection |
1.8% |
| Infective Exacerbation Of Chronic Obstructive Airways Disease |
1.8% |
| Nephrotic Syndrome |
1.8% |
| Prophylaxis |
1.8% |
| Bronchitis |
0.9% |
| Clostridial Infection |
0.9% |
| Depression |
0.9% |
| Dyslipidaemia |
0.9% |
| Erysipelas |
0.9% |
|
| Drug Interaction |
27.3% |
| Clostridium Difficile Colitis |
18.2% |
| Cholelithiasis |
9.1% |
| General Physical Health Deterioration |
9.1% |
| Presyncope |
9.1% |
| Renal Haemorrhage |
9.1% |
| Rhabdomyolysis |
9.1% |
| Thyroid Disorder |
9.1% |
|
